본문 바로가기(skip to contents)
한국원자력의학원
  • 정보공개
  • Home
  • Sitemap
통합검색
한국원자력의학원
  • 플랫폼구축 사업단소개
    • 인사말
    • 연혁
    • 조직도
    • 사업내용
    • CI 소개
  • 신약개발지원사업
    • 플랫폼구축사업
    • RI ADME
    • RI기반 바이오이미징
    • 방사성의약품 GLP
    • 방사성의약품 GMP
  • 연구협력
    • 연구협력
  • 기업입주안내
    • 기업입주안내
  • 자료실
    • 시설 소개
    • 장비 소개
    • 방사성의약품 자료실
    • 임상자원자 모집
  • 열린마당
    • 사업단 소식
    • 언론/보도자료
  • Contact Us
    • 찾아오시는길
    • 시험의뢰 문의

사업단 소식

Home > 플랫폼구축사업단 > 사업단소개 > 사업단 소식
입찰공고 보기
제목 BioCore and KDePRI enter into an MOU to advance radio-isotope detection technology (2019. 4.18)
작성일 2019-04-25 조회수 568
내용
BioCore and KDePRI enter into an MOU to advance radio-isotope detection technology 


On this date, BioCore, Korea's leading Contract Research Organization (CRO) for personalized medicine, entered into a Memorandum of Understanding (MOU) with the Korean Drug Development Platform using Radio-Isotope (KDePRI), located at Korean Institute of Radiological and Medical Sciences (KIRAMS; Nowon-gu, Seoul). The agreement was signed by the Director of New Drug Development Division, 오수연 of BioCore and  the Director of KDePRI, 심재훈. The agreement defines a mutually beneficial collaboration where BioCore will provide specialized sample processing and GLP oversight for clinical development studies of new drug molecules requiring radio-isotopes  In return KDePRI will provide access to its advanced radio-isotope detection technology and expert staff who are focused on accelerating drug development for Korean and Global Pharmaceutical Partners.

 


About KDePRI


KDePri is a government-affiliated institution that specializes in radiolabeled ADME, bioimaging and radiopharmaceutical production and analysis under GLP and GMP regulatory conditions.  It is houses state-of-the-art equipment run by experts in a purpose-built, 7-story facility.  KDePRI facilitates the application of radioisotopes to new drug development.  It welcomes any and all researchers and pharmaceutical companies to utilizes any of its many services.  

Contact yhlim@kirams.re.kr for more information.


About BioCore


BioCore is Korea's largest and oldest CRO, with a long history of providing high quality GLP clinical services for Bioequivalency and Phase 1 and 2 clinical development.  It is an integrated CRO that uses an array of bioanalyical tools coupled with patented DNA assays to address the rapidly growing need for personalized medicine.  BioCore is currently listed on the KONEX stock market. 

Contact syoh@bio-core.com at www.bio-core.com for more information.


 




 

첨부파일
목록